You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.
The Phase II DESTINY-CRC01 and DESTINY-Gastric01 underscore the importance of HER2 testing in patients with colorectal cancers and gastric cancers, respectively.
Investigators are building upon an initial case study that allowed them to assess how well ctDNA captured a cancer's full genomic heterogeneity compared to tissue biopsies.
In a Phase II study, the drug demonstrated superiority over investigator's choice of chemotherapy in patients with advanced disease.
The company submitted a supplemental NDA for the antibody drug conjugate based on objective response and overall survival data from the Phase II DESTINY-Gastric01 trial.
The analysis involving GI patients in Germany showed that integrating NGS and WES into practice identified more germline variants and identified unique treatment options.
The company also plans to submit a new drug application for avapritinib in mainland China in the first half of this year.
The trial evaluated the safety and preliminary activity of the single-agent therapy for FGFR2b-overexpressing gastric cancers.
The partnership aims to analyze the differences in the tumor microenvironments of cancer patients and use that to classify tumors and determine treatment prognosis.
Five Prime Therapeutics provided an update on the development of bemarituzumab and FPA150, and Gritstone Oncology discussed plans for its personalized immunotherapies.